Ansari Samaneh, Djalali Mahmoud, Mohammadzadeh Honarvar Niyaz, Mazaherioun Maryam, Zarei Mahnaz, Agh Fahimeh, Gholampour Zahra, Javanbakht Mohammad Hassan
Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, IR Iran.
Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, International Campus, Tehran University of Medical Sciences, Tehran, IR Iran.
Int J Endocrinol Metab. 2017 Jan 21;15(1):e40614. doi: 10.5812/ijem.40614. eCollection 2017 Jan.
Diabetes refers to a group of metabolic diseases with blood glucose of higher than normal ranges. Furthermore, n-3 polyunsaturated fatty acids are necessary for the regulation of the activity of human function. The effect of n-3 PUFA on diabetes has been investigated in animal studies, yet, the exact amount has not been set, to date. Irisin, as a new myokine, is released from skeletal muscle and Irisin levels decrease as a result of physical inactivity, overweightness, and obesity. Also, the reduction of serum irisin level is associated with development of insulin resistance and type 2 diabetes. This study was performed to assess the effects of n-3 PUFA supplementation on serum irisin level in patients with diabetes.
This randomized clinical trial included 43 patients with type 2 diabetes (21 patients in the placebo group and 22 patients in the n-3 PUFA supplement group). They were randomized to groups, one receiving 10 weeks of either n-3 PUFA supplement and the other the placebo (1250 mg capsule, three times per day). Samples were also matched by age, gender, and body mass index (BMI) in the 2 groups. Anthropometric measurements, demographic information and dietary intakes were obtained both before and after the intervention. Serum irisin levels were measured before and after the intervention using human irisin enzyme linked immunosorbent assay (ELISA) kit. Independent t-test was used to compare the mean outcomes between groups.
At baseline, irisin serum levels were not significantly different between the placebo and n-3 PUFA supplementation groups (P > 0.05). However, a significant change was observed between the groups after intervention (P = 0.04). Also there was a significant difference in mean change (after versus before the intervention) (P = 0.05). Compared to the placebo, n-3 PUFA supplementation decreased serum FBS and HbA1C (P = 0.036 and 0.001; respectively). Also, there were significant differences between changes of diastolic blood pressure and HOMA-IR after the intervention between the groups. The duration of illness was not considered as a confounding factor because there was no significant association between irisin level (after versus before the intervention) and the illness duration.
The current study indicated that n-3 PUFA supplementation with a dosage of 1250 mg three times per day, resulted in increased serum irisin level of diabetic patients.
糖尿病是指一组血糖高于正常范围的代谢性疾病。此外，n-3多不饱和脂肪酸对于调节人体功能活动是必需的。n-3多不饱和脂肪酸对糖尿病的影响已在动物研究中进行了调查，但迄今为止，确切的用量尚未确定。鸢尾素作为一种新的肌动蛋白，从骨骼肌中释放出来，由于缺乏运动、超重和肥胖，鸢尾素水平会降低。此外，血清鸢尾素水平的降低与胰岛素抵抗和2型糖尿病的发展有关。本研究旨在评估补充n-3多不饱和脂肪酸对糖尿病患者血清鸢尾素水平的影响。
这项随机临床试验纳入了43例2型糖尿病患者（安慰剂组21例，n-3多不饱和脂肪酸补充剂组22例）。他们被随机分组，一组接受10周的n-3多不饱和脂肪酸补充剂，另一组接受安慰剂（1250毫克胶囊，每日三次）。两组在年龄、性别和体重指数（BMI）方面也进行了匹配。在干预前后均获取人体测量数据、人口统计学信息和饮食摄入量。使用人鸢尾素酶联免疫吸附测定（ELISA）试剂盒在干预前后测量血清鸢尾素水平。采用独立t检验比较两组间的平均结果。
在基线时，安慰剂组和n-3多不饱和脂肪酸补充剂组之间的鸢尾素血清水平无显著差异（P>0.05）。然而，干预后两组间观察到显著变化（P=0.04）。干预前后的平均变化也有显著差异（P=0.05）。与安慰剂相比，补充n-3多不饱和脂肪酸可降低血清空腹血糖（FBS）和糖化血红蛋白（HbA1C）（分别为P=0.036和P=0.001）。此外，两组干预后舒张压和稳态模型评估胰岛素抵抗（HOMA-IR）的变化也存在显著差异。病程未被视为混杂因素，因为鸢尾素水平（干预后与干预前）与病程之间无显著关联。
当前研究表明，每天三次服用1250毫克的n-3多不饱和脂肪酸补充剂可提高糖尿病患者的血清鸢尾素水平。
